|
|
| | 3-Pyridinecarbonitrile, 6-[4-[(1,2,3,4,5,6-hexahydro-5-oxobenzo[h]-1,6-naphthyridin-8-yl)methyl]-1-piperazinyl]- Basic information |
| Product Name: | 3-Pyridinecarbonitrile, 6-[4-[(1,2,3,4,5,6-hexahydro-5-oxobenzo[h]-1,6-naphthyridin-8-yl)methyl]-1-piperazinyl]- | | Synonyms: | 3-Pyridinecarbonitrile, 6-[4-[(1,2,3,4,5,6-hexahydro-5-oxobenzo[h]-1,6-naphthyridin-8-yl)methyl]-1-piperazinyl]-;Nesuparib;Nesuparib, 10 mM in DMSO;6-(4-((5-Oxo-1,2,3,4,5,6-hexahydrobenzo[h][1,6]naphthyridin-8-yl)methyl)piperazin-1-yl)nicotinonitrile | | CAS: | 2055357-64-5 | | MF: | C23H24N6O | | MW: | 400.48 | | EINECS: | | | Product Categories: | | | Mol File: | 2055357-64-5.mol | ![3-Pyridinecarbonitrile, 6-[4-[(1,2,3,4,5,6-hexahydro-5-oxobenzo[h]-1,6-naphthyridin-8-yl)methyl]-1-piperazinyl]- Structure](CAS/20210305/GIF/2055357-64-5.gif) |
| | 3-Pyridinecarbonitrile, 6-[4-[(1,2,3,4,5,6-hexahydro-5-oxobenzo[h]-1,6-naphthyridin-8-yl)methyl]-1-piperazinyl]- Chemical Properties |
| Boiling point | 692.8±55.0 °C(Predicted) | | density | 1.36±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | form | Solid | | pka | 13.75±0.20(Predicted) | | color | White to off-white |
| | 3-Pyridinecarbonitrile, 6-[4-[(1,2,3,4,5,6-hexahydro-5-oxobenzo[h]-1,6-naphthyridin-8-yl)methyl]-1-piperazinyl]- Usage And Synthesis |
| Uses | Nesuparib (JPI-547) is an orally active PARP 1/2 and Tankyrase 1/2 inhibitor involved in the Wnt/β-catenin pathway. Nesuparib can induce cell cycle arrest and apoptosis and has anti-tumor activity. Nesuparib can be used to study cancer, neurological diseases and cardiovascular diseases[1][1][3]. | | IC 50 | PARP1; PARP2 | | References | [1] Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same. Patent WO2016200101A2.
[2] Im S A , et al.A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.[J].Journal of Clinical Oncology, 2021, 39(15_suppl):3113-3113.
[3] Oh K S, et al. JPI-547, a dual inhibitor of PARP/Tankyrase, shows promising antitumor activity against pancreatic cancers with homologous recombination repair deficiency or Wnt-addiction[J]. Cancer Research, 2023, 83(7_Supplement): 4496-4496. |
| | 3-Pyridinecarbonitrile, 6-[4-[(1,2,3,4,5,6-hexahydro-5-oxobenzo[h]-1,6-naphthyridin-8-yl)methyl]-1-piperazinyl]- Preparation Products And Raw materials |
|